17. Multiple system atrophy
107 clinical trials,   153 drugs   (DrugBank: 48 drugs),   59 drug target genes,   104 drug target pathways

Searched query = "Multiple system atrophy", "MSA-C", "MSA-P", "Olivopontocerebellar atrophy", "OPCA", "Striatonigral degeneration", "Shy-Drager syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00211224
(ClinicalTrials.gov)
April 200013/9/2005Neuroprotection and Natural History in Parkinson's Plus Syndromes (NNIPPS)Phase 3 Study of Riluzole in Multiple System Atrophy (MSA) and Progressive Supranuclear Palsy (PSP) (Parkinson's Plus Syndromes)Multiple System Atrophy;Progressive Supranuclear PalsyDrug: RiluzoleKing's College LondonAssistance Publique - Hôpitaux de Paris;University of Ulm;Aventis PharmaceuticalsTerminated30 Years80 YearsBoth800Phase 3United Kingdom